Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer
News
A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, ... Read more